← Back to Search

AI-Enhanced ECG for Cardiac Amyloidosis

N/A

Waitlist Available

Led By Angela Dispenzieri, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial assesses whether a new AI-based tool can improve the diagnosis of cardiac amyloidosis, a heart condition.

Who is the study for?

This trial is for Mayo Clinic providers who agree to participate and are involved in caring for adult patients within cardiology or hematology departments. There are no specific exclusion criteria, making it broadly accessible to these healthcare professionals.Check my eligibility

What is being tested?

The study is evaluating an innovative AI-powered tool that analyzes ECG readings to help detect cardiac amyloidosis more effectively. This could potentially improve diagnosis rates of this heart condition.See study design

What are the potential side effects?

Since the intervention involves using an AI algorithm on ECG data rather than a medical treatment or drug, there are no direct side effects associated with its use in this trial.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To determine if AI ECG algorithm and enhanced algorithms and education enable earlier diagnosis of cardiac amyloidosisProtocol for a Pragmatic Cluster Randomized Clinical Trial (PREDICT-AMY)

Secondary outcome measures

To assess differential costs between the intervention arm and the standard of care arm

Electrocardiogram

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Notification of the AI ECG algorithm and the A3E scoresExperimental Treatment1 Intervention

Provider-facing recommendation report that alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders

Group II: Usual CareActive Control1 Intervention

No alerts to provider for positive AI ECG Amyloid Score, standardized amyloid order set, diagnostic algorithm and reminders

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,207 Previous Clinical Trials

3,766,940 Total Patients Enrolled

1 Trials studying Cardiac Amyloidosis

100 Patients Enrolled for Cardiac Amyloidosis

Angela Dispenzieri, MDPrincipal InvestigatorMayo Clinic

3 Previous Clinical Trials

156 Total Patients Enrolled

Media Library

Notification of the AI ECG algorithm and the A3E scores Clinical Trial Eligibility Overview. Trial Name: NCT05557162 — N/A

Cardiac Amyloidosis Research Study Groups: Notification of the AI ECG algorithm and the A3E scores, Usual Care

Cardiac Amyloidosis Clinical Trial 2023: Notification of the AI ECG algorithm and the A3E scores Highlights & Side Effects. Trial Name: NCT05557162 — N/A

Notification of the AI ECG algorithm and the A3E scores 2023 Treatment Timeline for Medical Study. Trial Name: NCT05557162 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment efforts underway for this research study?

"The information posted to clinicaltrials.gov suggests that this specific trial, which was presented on October 31, 2022 and last modified 14 days later, is not enrolling patients presently—however there are 97 alternative medical studies in need of participants currently."

Answered by AI

How many health centers are currently administering this research program?

"This trial has been deployed in multiple locations, such as the Mayo Clinic Rochester in Rochester, Minnesota; Mayo Clinic Health System in Eau Claire, Wisconsin; and Mayo Clinic Arizona in Scottsdale, Arizona."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

Angela Dispenzieri 2023. "Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05557162.

All > Amyloidosis